NO20053076L - Farmasoytisk formulering med en uloselig aktiv forbindelse. - Google Patents

Farmasoytisk formulering med en uloselig aktiv forbindelse.

Info

Publication number
NO20053076L
NO20053076L NO20053076A NO20053076A NO20053076L NO 20053076 L NO20053076 L NO 20053076L NO 20053076 A NO20053076 A NO 20053076A NO 20053076 A NO20053076 A NO 20053076A NO 20053076 L NO20053076 L NO 20053076L
Authority
NO
Norway
Prior art keywords
active compound
pharmaceutical formulation
insoluble active
particulate
less
Prior art date
Application number
NO20053076A
Other languages
English (en)
Other versions
NO20053076D0 (no
Inventor
Jeffrey G Weers
Thomas E Tarara
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32713146&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20053076(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of NO20053076D0 publication Critical patent/NO20053076D0/no
Publication of NO20053076L publication Critical patent/NO20053076L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

En farmasøytisk formulering for pulmonal administrering omfatter et partikkelformig materiale som omfatter en partikkelformig aktiv forbindelse i en lipidmatriks, idet den aktive forbindelsen har en løselighet i vann på mindre enn 1,0 mg/ml. I én versjon har minst 90% av den partikkelformige aktive forbindelsen i den farmasøytiske formuleringen en geometrisk diameter på mindre enn 3 µm. I en annen versjon omfatter den uløselige aktive forbindelsen amphotericin B. Det partikkelformige materialet kan ha en størrelse og form som tillater at den trykkforstøvede farmasøytiske formuleringen blir levert til dypet av lungen.
NO20053076A 2002-12-31 2005-06-23 Farmasoytisk formulering med en uloselig aktiv forbindelse. NO20053076L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43721002P 2002-12-31 2002-12-31
PCT/US2003/041703 WO2004060351A2 (en) 2002-12-31 2003-12-31 Pharmaceutical formulation with an insoluble active agent for pulmonary administration

Publications (2)

Publication Number Publication Date
NO20053076D0 NO20053076D0 (no) 2005-06-23
NO20053076L true NO20053076L (no) 2005-09-13

Family

ID=32713146

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053076A NO20053076L (no) 2002-12-31 2005-06-23 Farmasoytisk formulering med en uloselig aktiv forbindelse.

Country Status (18)

Country Link
US (1) US20040156792A1 (no)
EP (1) EP1589947B2 (no)
JP (1) JP2006513236A (no)
KR (1) KR20050095838A (no)
CN (1) CN1741789A (no)
AU (1) AU2003300137A1 (no)
BR (1) BR0317810A (no)
CA (1) CA2511523C (no)
EA (1) EA200501001A1 (no)
ES (1) ES2589578T5 (no)
HU (1) HUP0500846A3 (no)
MX (1) MXPA05007158A (no)
NO (1) NO20053076L (no)
PL (1) PL378270A1 (no)
PT (1) PT1589947T (no)
TR (1) TR200502522T2 (no)
WO (1) WO2004060351A2 (no)
ZA (1) ZA200505155B (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
CA2382133C (en) 2000-05-10 2010-11-23 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
JP2005514393A (ja) * 2001-12-19 2005-05-19 ネクター セラピューティクス アミノグリコシドの肺への供給
CA2511555A1 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Aerosolizable pharmaceutical formulation for fungal infection therapy
EP1635786A2 (en) 2003-05-28 2006-03-22 Nektar Therapeutics Spray drying of an alcoholic aqueous solution for the manufacture of a water-insoluble active agent microparticle with a partial or complete amino acid and/or phospholipid coat
US8513204B2 (en) * 2004-06-21 2013-08-20 Novartis Ag Compositions comprising amphotericin B, mehods and systems
US9061027B2 (en) 2004-08-27 2015-06-23 Board Of Regents, The University Of Texas System Enhanced delivery of drug compositions to treat life threatening infections
CA2623256A1 (en) * 2005-09-29 2007-04-12 Nektar Therapeutics Receptacles and kits, such as for dry powder packaging
ITMI20051999A1 (it) * 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
US20120128728A1 (en) * 2005-12-28 2012-05-24 Novartis Pharma Ag Compositions Comprising Amphotericin B
EP2497484A3 (en) * 2006-02-22 2012-11-07 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
DE102006053375A1 (de) * 2006-11-10 2008-05-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Mischung von Pulvern
BRPI0815382A2 (pt) * 2007-07-31 2015-02-10 Otsuka Pharma Co Ltd Métodos para a produção de suspensão de aripiprazol e formulação de secagem por congelamento
EP2050437A1 (en) * 2007-10-15 2009-04-22 Laboratoires SMB Improved pharmaceutical dry powder compositions for inhalation.
PL220269B1 (pl) 2008-04-21 2015-09-30 Przedsiębiorstwo Produkcji Farmaceutycznej Hasco Lek Spółka Akcyjna Kompozytowy nośnik leków proszkowych, sposób wytwarzania nośnika leków oraz urządzenie do wytwarzania cząstek nośnika kompozytowego
MX2010012452A (es) 2008-05-15 2011-03-15 Novartis Ag Star Suministro pulmonar de una fluoro-quinolona.
CA2755809C (en) 2009-03-18 2014-02-18 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
US9724664B2 (en) 2009-03-27 2017-08-08 Bend Research, Inc. Spray-drying process
GB0908129D0 (en) * 2009-05-12 2009-06-24 Innovata Ltd Composition
TR200904500A2 (tr) 2009-06-10 2009-10-21 Öner Levent Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları.
US9084944B2 (en) 2010-09-03 2015-07-21 Bend Research, Inc. Spray-drying apparatus and methods of using the same
WO2012031129A2 (en) 2010-09-03 2012-03-08 Bend Research, Inc. Spray-drying apparatus and methods of using the same
US9248584B2 (en) 2010-09-24 2016-02-02 Bend Research, Inc. High-temperature spray drying process and apparatus
CN103228266B (zh) 2010-10-29 2017-11-14 健康科学西部大学 三元混合物制剂
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
US20150224202A1 (en) * 2014-02-03 2015-08-13 The Board Of Trustees Of The Leland Stanford Junior University Formulations and uses for microparticle delivery of zinc protoporphyrins
US11364203B2 (en) 2014-10-31 2022-06-21 Bend Reserch, Inc. Process for forming active domains dispersed in a matrix
CN104587457B (zh) * 2015-01-13 2017-03-22 广东海大畜牧兽医研究院有限公司 一种利用难溶或不溶蛋白、多肽抗原制备纳米微粒疫苗的方法
RU2720573C2 (ru) * 2015-12-24 2020-05-12 Филип Моррис Продактс С.А. Капсула с частицами никотина
GB2581301A (en) 2016-02-01 2020-08-12 Incarda Therapeutics Inc Combining electronic monitoring with inhaled pharmacological therapy to manage atrial arrhythmias including atrial fibrillation
CA3060702A1 (en) 2017-05-10 2018-11-15 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
EP3644962A1 (en) * 2017-06-28 2020-05-06 Philip Morris Products S.a.s. Container with particles for use with inhaler
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
GB201817865D0 (en) * 2018-11-01 2018-12-19 Nicoventures Trading Ltd Aerosolisable formulation
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US437210A (en) 1890-09-30 Electric street-car
SE408265B (sv) * 1975-12-12 1979-06-05 Draco Ab Anordning for koldioxiddriven endosaerosol, avsedd for inhalering
US4247066A (en) * 1978-02-21 1981-01-27 General Dynamics Corporation Airfoil variable cambering device and method
IT1116047B (it) * 1979-04-27 1986-02-10 Sigma Tau Ind Farmaceuti Dispositivo per la rapida inalazione di farmaci in polvere da parte di persone sofferenti di asma
DE3634952A1 (de) * 1986-10-14 1988-04-21 Bayer Ag Imidazo-pyrrolo-pyridin-derivate
US5049388A (en) * 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
KR100246082B1 (ko) * 1991-07-02 2000-04-01 인헤일, 인코오포레이티드 에어로졸화된약제를전달하는방법및장치
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5785049A (en) * 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
JP3388896B2 (ja) * 1994-08-08 2003-03-24 株式会社日立ユニシアオートモティブ 吸入式投薬器
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
KR19980703876A (ko) * 1995-04-14 1998-12-05 스티븐 엘. 허스트 분산성이 개선된 분말화된 약학적 조성물
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6503480B1 (en) * 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
AU6014098A (en) * 1996-12-31 1998-07-31 Inhale Therapeutic Systems Aerosolized hydrophobic drug
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
ES2205560T5 (es) * 1997-09-29 2013-04-16 Novartis Ag Preparaciones estabilizadas para usar en inhaladores de dosis medida
US6257233B1 (en) * 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
AU4602399A (en) 1998-06-30 2000-01-24 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) Prolonged release ophthalmic compositions containing a fluoroquinolone
US20010036481A1 (en) * 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
CA2382133C (en) 2000-05-10 2010-11-23 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US6357490B1 (en) * 2000-08-22 2002-03-19 Advanced Inhalation Research, Inc. System, method and apparatus for filling containers
CA2432319A1 (en) * 2000-12-21 2002-07-18 Nektar Therapeutics Pulmonary delivery of polyene antifungal agents

Also Published As

Publication number Publication date
CA2511523A1 (en) 2004-07-22
ES2589578T3 (es) 2016-11-15
EA200501001A1 (ru) 2005-12-29
EP1589947A2 (en) 2005-11-02
BR0317810A (pt) 2005-11-29
EP1589947B8 (en) 2016-08-24
EP1589947B1 (en) 2016-06-15
CN1741789A (zh) 2006-03-01
EP1589947B2 (en) 2019-01-30
US20040156792A1 (en) 2004-08-12
JP2006513236A (ja) 2006-04-20
MXPA05007158A (es) 2005-09-21
CA2511523C (en) 2013-10-15
AU2003300137A1 (en) 2004-07-29
HUP0500846A3 (en) 2008-10-28
PL378270A1 (pl) 2006-03-20
ES2589578T5 (es) 2019-07-23
WO2004060351A3 (en) 2004-09-30
PT1589947T (pt) 2016-09-05
TR200502522T2 (tr) 2005-09-21
ZA200505155B (en) 2006-04-26
WO2004060351A2 (en) 2004-07-22
HUP0500846A2 (en) 2008-05-28
NO20053076D0 (no) 2005-06-23
KR20050095838A (ko) 2005-10-04

Similar Documents

Publication Publication Date Title
NO20053076L (no) Farmasoytisk formulering med en uloselig aktiv forbindelse.
UY30537A1 (es) Formulaciones de flibanserina y metodo para fabricarlas
BR9503386A (pt) Formulaçao farmacêutica comprimido dispersivel e processo para a fabricaçao de comprimidos dispersíveis contendo cloridrato de fluoxetina
NO20080827L (no) Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon
WO2006102446A3 (en) Multi-particulate, modified-released colonic composition
NO20073959L (no) Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller
AR018143A1 (es) Formulacion para preparar un comprimido de desintegracion rapida, comprimidos de desintegracion rapida, especialmente comprimidos de desintegracionrapida en la boca
ATE355829T1 (de) Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung
NO20081889L (no) Fast vaksine formulering
RS52577B (en) ONE-DAY OXYCODON FORMULATIONS
NO20082988L (no) Vedvarende frigivningsformulering innbefattende oktreotid og to eller flere polylaktid-ko-glykolidpolymerer
NO341573B1 (no) Faste formuleringer av ospemifen og fremgangsmåte for fremstilling av ospemifen
CA2273420A1 (fr) Comprime matriciel permettant la liberation prolongee de gliclazide apres administration par voie orale
ATE541562T1 (de) Ibuprofen-suspension
TNSN97134A1 (fr) Comprime de maleate de trimebutine pellicule
ITMI20022292A1 (it) 9a-azalidi ad attivita' antiinfiammatoria.
MXPA03005221A (es) Composicion farmaceutica de dronedarona para administracion parenteral.
JP2024001364A5 (no)
DE60102590D1 (de) Darreichungsformen zur behandlung von oralen mykosen
NO20054417L (no) Fremgangsmate for fremstilling av farmasoytiske preperater i form av fibratholdige tabletter og de derved fremstilte tabletter
UA89656C2 (ru) Фармацевтическая композиция, которая диспергируется перорально, и способ ее приготовления
CO5550418A2 (es) Formulaciones antihistaminicas para formas de dosificacion de capsula blanda
WO2007144902A8 (en) Chewable bilayer tablet formulation
TW200420304A (en) Orally administrable pharmaceutical compositions and methods for preventing food-drug interaction
IL182549A0 (en) Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application